The CV benefits were variable among the different available GLP-1 RAs; some randomized controlled trials demonstrated that liraglutide, dulaglutide, semaglutide, and albiglutide reduced the rate of CV events in T2DM patients (6–9), while other clinical trials concluded that lixisenatide and exenatide did not significantly improve CV outcomes in such patients (10, 11). This evidence concerns the gene GCG and type 2 diabetes mellitus.